PrEP Biopharm

About PrEP Biopharm

PrEP Biopharm is a development stage biopharmaceutical company focused on creating innovative treatments for respiratory viral infections. Operating in the pharmaceutical industry, PrEP Biopharm primarily serves healthcare providers and patients who are affected by upper respiratory viral infections (URVIs). The company’s core product, PrEP 001, is a phase 2 nasal spray designed to stimulate the host's innate immune response, offering protection against a wide range of respiratory viruses, including influenza, rhinovirus, SARS, MERS, RSV, and COVID-19.

PrEP Biopharm operates in the global healthcare market, targeting both pandemic and non-pandemic settings. The business model is centered around the research, development, and eventual commercialization of its proprietary nasal spray. Revenue generation is expected to come from product sales, licensing agreements, and potential partnerships with larger pharmaceutical companies.

The company aims to address the significant economic and health burden caused by URVIs, which affect millions of people annually. By providing a broad-spectrum antiviral solution, PrEP Biopharm seeks to reduce the incidence and severity of these infections, ultimately lowering healthcare costs and improving patient outcomes.